Literature DB >> 29030273

Heterologous production of myxobacterial α-pyrone antibiotics in Myxococcus xanthus.

Hilda Sucipto1, Domen Pogorevc2, Eva Luxenburger2, Silke C Wenzel3, Rolf Müller4.   

Abstract

Myxopyronins (MXN) and corallopyronins (COR) are structurally related α-pyrone antibiotics from myxobacteria that represent a highly promising compound class for the development of broad-spectrum antibacterial therapeutic agents. Their ability to inhibit RNA polymerase through interaction with the "switch region", a novel target, distant from previously characterized RNA polymerase inhibitors (e.g. rifampicin), makes them particularly promising candidates for further research. To improve compound supply for further investigation of MXN, COR and novel derivatives of these antibacterial agents, establishment of an efficient and versatile microbial production platform for myxobacterial α-pyrone antibiotics is highly desirable. Here we describe design, construction and expression of a heterologous production and engineering platforms for MXN and COR to facilitate rational structure design and yield improvement approaches in the myxobacterial host strain Myxococcus xanthus DK1622. Optimization of the cultivation medium yielded significantly higher production titers of MXN A at around 41-fold increase and COR A at around 25-fold increase, compared to the standard CTT medium.
Copyright © 2017 International Metabolic Engineering Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29030273     DOI: 10.1016/j.ymben.2017.10.004

Source DB:  PubMed          Journal:  Metab Eng        ISSN: 1096-7176            Impact factor:   9.783


  12 in total

1.  Engineering Pseudochelin Production in Myxococcus xanthus.

Authors:  Juliane Korp; Lea Winand; Angela Sester; Markus Nett
Journal:  Appl Environ Microbiol       Date:  2018-10-30       Impact factor: 4.792

2.  Genome mining reveals uncommon alkylpyrones as type III PKS products from myxobacteria.

Authors:  Joachim J Hug; Fabian Panter; Daniel Krug; Rolf Müller
Journal:  J Ind Microbiol Biotechnol       Date:  2018-12-01       Impact factor: 3.346

Review 3.  Genetic platforms for heterologous expression of microbial natural products.

Authors:  Jia Jia Zhang; Xiaoyu Tang; Bradley S Moore
Journal:  Nat Prod Rep       Date:  2019-06-14       Impact factor: 13.423

4.  Structure and biosynthesis of sorangipyranone - a new γ-dihydropyrone from the myxobacterial strain MSr12020.

Authors:  Dorothy A Okoth; Joachim J Hug; Attila Mándi; Tibor Kurtán; Ronald Garcia; Rolf Müller
Journal:  J Ind Microbiol Biotechnol       Date:  2021-06-04       Impact factor: 4.258

Review 5.  Refactoring biosynthetic gene clusters for heterologous production of microbial natural products.

Authors:  Lei Li; Logan W Maclntyre; Sean F Brady
Journal:  Curr Opin Biotechnol       Date:  2021-01-18       Impact factor: 10.279

6.  Synthetic biology approaches and combinatorial biosynthesis towards heterologous lipopeptide production.

Authors:  Fu Yan; Christian Burgard; Alexander Popoff; Nestor Zaburannyi; Gregor Zipf; Josef Maier; Hubert S Bernauer; Silke C Wenzel; Rolf Müller
Journal:  Chem Sci       Date:  2018-08-08       Impact factor: 9.825

7.  Setting Our Sights on Infectious Diseases.

Authors:  Manu De Rycker; David Horn; Bree Aldridge; Richard K Amewu; Clifton E Barry; Frederick S Buckner; Sarah Cook; Michael A J Ferguson; Nathalie Gobeau; Jennifer Herrmann; Paul Herrling; William Hope; Jennifer Keiser; Maria Jose Lafuente-Monasterio; Paul D Leeson; Didier Leroy; Ujjini H Manjunatha; James McCarthy; Timothy J Miles; Valerie Mizrahi; Olena Moshynets; Jacquin Niles; John P Overington; John Pottage; Srinivasa P S Rao; Kevin D Read; Isabela Ribeiro; Lynn L Silver; Jen Southern; Thomas Spangenberg; Shyam Sundar; Caitlin Taylor; Wes Van Voorhis; Nicholas J White; Susan Wyllie; Paul G Wyatt; Ian H Gilbert
Journal:  ACS Infect Dis       Date:  2019-12-06       Impact factor: 5.084

Review 8.  Natural products in drug discovery: advances and opportunities.

Authors:  Atanas G Atanasov; Sergey B Zotchev; Verena M Dirsch; Claudiu T Supuran
Journal:  Nat Rev Drug Discov       Date:  2021-01-28       Impact factor: 112.288

9.  Myxopyronin B inhibits growth of a Fidaxomicin-resistant Clostridioides difficile isolate and interferes with toxin synthesis.

Authors:  Madita Brauer; Jennifer Herrmann; Daniela Zühlke; Rolf Müller; Katharina Riedel; Susanne Sievers
Journal:  Gut Pathog       Date:  2022-01-06       Impact factor: 4.181

Review 10.  Metabolic and Biosynthetic Diversity in Marine Myxobacteria.

Authors:  Katja Gemperlein; Nestor Zaburannyi; Ronald Garcia; James J La Clair; Rolf Müller
Journal:  Mar Drugs       Date:  2018-09-05       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.